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Glycosylation of therapeutically relevant proteins such as monoclonal antibodies (mAbs), is critical as it can offer 
increased drug efficiency, efficacy and half-life. Therefore, the production of modern biotherapeutics focuses on 
controlling the protein glycosylation profile using various methods. Currently, the dominating method is the 
traditional cell-line engineering of host cells such as mammalian cells. The main goal is to produce mAbs with a 
human-like glycosylation pattern. However, this approach often struggles due to high sensitivity to the 
fermentation environment making it difficult to scale up and control. The latter can lead to structural 
heterogeneity amongst the products which can be immunogenic. In addition to the in vivo methods, there are 
many in vitro techniques such as chemoselective or enzymatic glycosylation. However, they are often limited by 
the difficult implementation and, as before, product heterogeneity due to lack of control over the enzymatic 
reactions. 
 
In line with the need to control glycosylation in the production of therapeutic proteins, we propose an artificial 
Golgi reactor for in vitro glycosylation. By expressing selected glycosyltransferases and immobilizing them on 
solid supports we can achieve sequential enzymatic reactions required for protein glycosylation. The spatial 
separation will allow strict control over the reaction conditions while addressing enzyme promiscuity. Both 
should enhance product quality. Furthermore, we aim to perform a single-step glycosyltransferases 
purification/immobilization. Thanks to that, as well as the modularity of our design, the proposed system would 
be more sustainable and easily tailored for each application, thus producing any desired glycoform to 
homogeneity. A detailed mathematical approach to design and optimisation of the proposed artificial Golgi 
reactor focusing on mAb therapeutics has been published [1]. The authors report an optimisation of the reactor 
design and operational parameters that directs the whole process towards the desired glycan structure. 
In this research project, we have achieved expression and in vivo biotinylation of Nicotiana Tabacum GnTI 
(NtGnTI) and human GalT in E. coli. The biotinylated enzymes were successfully bound to streptavidin beads 
and used for artificial glycan synthesis. NtGnTI and GalT reacted in a sequential fashion to produce the glycan 
GalGlcNAcMan5GlcNAc2, as confirmed with MALDI/TOF MS analysis. In the future, we aim in extending the 
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